中国医患共同决策心血管研究发布

2016-12-09 记者 董杰 医师报

研究概况:近日,大连医科大学附属第一医院黄榕翀教授团队发表的一项临床注册研究(中国他汀选择)显示,中国医生采用临床医患共同决策方式(SDM),对于提高稳定性冠心病患者临床决策中药物(他汀)依从性是可行的。(PatientPrefer Adherence. 2016,10:2341)研究全程均进行录像或录音,入组稳定性冠心病患者86例,对患者进行个体化危险评分后,采用在线决策工具帮助患者进行他汀选择

研究概况:近日,大连医科大学附属第一医院黄榕翀教授团队发表的一项临床注册研究(中国他汀选择)显示,中国医生采用临床医患共同决策方式(SDM),对于提高稳定性冠心病患者临床决策中药物(他汀)依从性是可行的。(PatientPrefer Adherence. 2016,10:2341)

研究全程均进行录像或录音,入组稳定性冠心病患者86例,对患者进行个体化危险评分后,采用在线决策工具帮助患者进行他汀选择:与患者交代不服用、服用小剂量他汀和服用大剂量他汀后,未来十年患者心脏事件总风险下降情况。并交代他汀服用后可能出现的不良反应及发生率、服用方式、花费情况及心脏外获益等,给患者选择的时间和机会,以决定是否服用他汀(至少十年)以及服用剂量(图1)。


所有患者要求随访1年。研究录像或录音由经过培训的三名医生分别进行评分,以评价此项研究中医生和患者参与SDM的程度和质量(即是否能够高质量完成SDM全过程)。

结果显示,来自国内两家大学附属医院的7名心内科中青年医生接受培训后,Fidelity评分为10分。Fidelity评分是评价SDM过程中医生是否能很好地将SDM各环节内容向患者说明的评价体系(分值为6~10分,总分10分),说明中国医生可以高质量完成SDM过程。

然而,另一项有关中国患者是否能在医生引导下很好地完成SDM过程的评价体系OPTION(即患者参与度,分值为3~32分,总分48分)显示,患者平均分为21分,略低于国外SDM研究患者参与度评价分数。

研究同时发现,部分中国医生与患者沟通时患者参与度很好(OPTION 25~28分),而也有部分医生的患者参与度很差(OPTION 11~13分),质量高低与医生地域、性别、患者因素(包括性别、年龄、合并疾病状态、受教育程度、是否有医疗保险、生活区域、收入水平等)无关。

进一步分析发现,SDM时间长(即沟通时间多)、医生进行SDM经验增加、医生临床经验多(工作时间长)及研究前开展患者教育可能有助于提高患者SDM参与度。

该研究为前瞻性、探索性、非对照研究,尽管缺乏随机对照研究。1年随访显示,当初选择他汀治疗的患者中,94.5%能坚持应用他汀,而相应主要不良心血管事件发生率较低(2.9%),这一初步结果可能为提高药物治疗依从性提供新的决策手段。

据悉,该研究团队于2014-2016年在5家中心开展了更大规模的他汀选择中国患者研究,目前已完成数据收集,也期待相关结果为中国SDM研究提供更多数据。研究得到复旦大学附属中山医院葛均波院士和北京大学第一医院霍勇教授支持,由美国梅奥诊所转化医学中心KER研究室Henry H. Ting和VictorM. Montori两位教授对医生团队面授培训,并提供研究所需的在线决策工具(他汀选择)。
 
研究者说:


黄榕翀教授指出,SDM通过让患者加入医疗决策过程,与医生沟通,充分了解不同医疗决策选择的风险与获益后,患者再与医生讨论,最后做出医疗决策的过程。尤其适用于某些医疗决策风险与获益相当,医患均难以做出选择的情况。

国外研究发现,SDM有助于提高患者满意度,加强医患间信任,提高药物治疗依从性,并一定程度改善疗效。目前多数研究集中于肿瘤治疗、急诊决策、慢性疾病治疗等领域。亚洲地区仅香港、马来西亚、日本等国家及地区已经开展或正在开展SDM研究,但亚洲地区心血管病诊治领域尚属空白。该研究也是中国心内科医生团队的一次尝试,探讨在中国应用SDM开展临床研究的可行性,其研究结果将为我国SDM的临床应用提供依据。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-23 李东泽

    很好,不错,以后会多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-15 李东泽

    很好,不错,以后会多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-12 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-12 邓启付

    医患共同决策能确保用药的规范性

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-11 邓启付

    医患共同研究好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-11 millore
  8. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-10 邓启付

    对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1812460, encodeId=be4f1812460e3, content=<a href='/topic/show?id=4ad789e3093' target=_blank style='color:#2F92EE;'>#血管研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89730, encryptionId=4ad789e3093, topicName=血管研究)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Fri Jul 21 23:42:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165095, encodeId=54a816509541, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Dec 23 10:22:39 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163090, encodeId=4711163090d8, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Dec 15 19:56:14 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162146, encodeId=2aea1621464a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Mon Dec 12 09:36:52 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=162078, encodeId=c5b41620e866, content=医患共同决策能确保用药的规范性, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon Dec 12 06:54:25 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161896, encodeId=364e161896e4, content=医患共同研究好, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Dec 11 09:07:02 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284642, encodeId=7146128464238, content=<a href='/topic/show?id=da9934342b5' target=_blank style='color:#2F92EE;'>#医患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34342, encryptionId=da9934342b5, topicName=医患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541781, encodeId=5d861541e8122, content=<a href='/topic/show?id=e8ca3108823' target=_blank style='color:#2F92EE;'>#决策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31088, encryptionId=e8ca3108823, topicName=决策)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 11 01:42:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161591, encodeId=9b9f1615911b, content=对于不服药一组,假如在随访过程中患者出现临床症状会不会给药。这项研究也有预案吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 07:00:41 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161590, encodeId=2f79161590c5, content=这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sat Dec 10 06:58:47 CST 2016, time=2016-12-10, status=1, ipAttribution=)]
    2016-12-10 邓启付

    这是一个系统而繁杂的过程,关键是患者是不是真真切切配合。

    0

相关资讯

从美国总统选举所想到的——我眼中的胡大一老师

近日,两个古稀老人竞选美国总统传遍朋友圈及各大网站,特朗普和希拉里,两个70岁的人如此为工作拼博,一切懒惰都是那么的苍白。希拉里,从第一夫人,到美国国务卿,到离第一个女总统只差1%的选票,虽败犹荣。特朗普,从一个商人直接到总统,一个身价40亿的老人,70岁的生活是竞选总统,当总统!当然,特朗普和希拉里离自己生活比较遥远,但另一个刚过70岁的老人,所经历的奋斗的历程,却正在切身感受,这个人就是我的博

二甲双胍这20问,共识怎么说?

65岁以上老年患者如何使用二甲双胍?肾功能不全的T2DM 患者使用二甲双胍应注意哪些问题?二甲双胍是否具有抗肿瘤作用?......这些有关二甲双胍的常见问题,看最新的《二甲双胍临床应用专家共识(2016版)》如何说明!近日,国内内分泌临床专家、药学专家对2014年版《二甲双胍临床应用专家共识》进行了更新,制定了《二甲双胍临床应用专家共识(2016版)》。小编这边介绍关于二甲双胍在特殊人群中的使

Circulation:收缩压越高,血栓风险越低?

传统的心血管疾病(CVD)危险因素与静脉血栓栓塞(VTE)之间的关联还存在很多争议。我们进行个体水平的随机效应荟萃分析,包括9项前瞻性研究,测量了基线CVD风险因素,且验证了VTE事件。VTE事件包括肺栓塞(PE)和深静脉血栓形成(DVT)。该研究包括244865名参与者,平均随访4.7−19.7 年,共发生了4910例VTE事件。调整年龄、性别、体重指数后,高血压发生VTE事件的HR为0.98

他汀类药物治疗可降低AS+PsA患者的心血管风险和总死亡率

根据美国风湿病学会年会上提交的调查结果显示,使用他汀类药物可以让强直性脊柱炎+银屑病关节炎患者的死亡率下降32%。 Amar Oza博士和同事们对2904例强直性脊柱炎(AS)+银屑病关节炎(PsA)患者进行了研究,研究他汀类药物对这类患者的生存益处。 平均随访时间为5.3年,他汀类使用者中死亡人数为271例;对照组5.15年的随访期间内,死亡人数为376例。他汀类药物使用组的死亡率为

JAMA:太空旅行,您的心血管遭得住吗?

越来越多的太空机构和私人公司计划在未来的几十年里载人飞行进入太空,了解辐射的持续健康效应将变得越来越重要,对人类太空探索领域也是至关重要的。 Michael D. Delp博士就航天对动物的心血管系统影响研究超过2年,他发现,在火星任务中遇到的辐射和剂量让动物出现血管内皮功能障碍,让其更易患动脉粥样硬化。 那么航天对航空员的心血管有啥影响? 1968年到1972年前往月球的阿波罗